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Background: Very few studies having decision support systems as an intervention report on patient outcomes for
cardiovascular disease in the Western world. The potential role of decision support system for the management of
blood pressure among Indian hypertensives remains unclear. We propose a cluster randomised trial that aims to
test the effectiveness and cost effectiveness of DSS among Indian hypertensive patients.
Methods: The trial design is a cluster randomised community intervention trial, in which the participants would be
adult male and female hypertensive patients, in the age group of 35 to 64 years, reporting to the Primary Health
Care centres of Mahabubnagar district, Andhra Pradesh, India. The objective of the study is to test the effectiveness
and compare the cost effectiveness and cost utility among hypertensive subjects randomized to receive either
decision support system or a chart based algorithmic support system in urban and rural areas of a district in the
state of Andhra Pradesh, India (baseline versus 12 months follow up). The primary outcome would be a comparison
of the systolic blood pressure at 0 and 12 months among hypertensive patients randomized to receive the decision
support system or the chart based algorithmic support system. Computer generated randomisation and an
investigator and analyser blinded method would be followed. 1600 participants; 800 to each arm; each arm having
eight clusters of hundred participants each have been recruited between 01 August 2011 - 01 March 2012. A twelve
month follow up will be completed by March 2013 and results are expected by April 2013.
Discussion: This cluster randomized community intervention trial on DSS will enable policy makers to find out the
effectiveness, cost effectiveness and cost utility of decision support system for management of blood pressure
among hypertensive patients in India. Most of the previous studies on decision support system have focused on
physician performance, adherence and on preventive care reminders. The uniqueness of the proposed study lies in
finding out the effectiveness of a decision support system on patient related outcomes.
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Compared with all other countries, India suffers the highest
loss in Potentially Productive Years of Life Lost (PPYLL),
due to deaths from cardiovascular disease in people aged
35–64 years (92 million PPYLL in 2000, with a projected
loss of 17.9 million PPYLL by 2030) [1]. CVD accounted for
29% of deaths and 11% of all Disability Adjusted Life Years
(DALYs) in India (all ages, 2005) [2]. Hypertension is
directly responsible for 57% of all stroke deaths and 24% of
all coronary heart disease deaths in India [3]. The World
Health Organization rates hypertension as one of the most
important causes of premature death worldwide [4]. The
global and regional burden of disease and risk factors study
(2001), in a systematic analysis of population health data for
attributable deaths and attributable disease burden, has
ranked Hypertension in South Asia as second only to child
underweight for age [5].
In an analysis of worldwide data for the global burden of
hypertension, 20.6% of Indian males and 20.9% of Indian
females were suffering from hypertension in 2005 [6]. The
rates for hypertension in % are projected to go up to 22.9
and 23.6 for Indian males and females respectively by 2025
[6]. Recent studies from India have shown the prevalence
of hypertension to be 25% in urban and 10% in rural
subjects in India [3,7-9].
However, only about 25.6% of treated patients had their
blood pressure under control, in a multi center study from
India on awareness, treatment and adequacy of control of
hypertension [10].
Decision support systems have been defined as the
tools that help clinicians decide on a course of action
in response to an understanding of the patient’s sta-
tus. These have been devised to improve the manage-
ment of hypertension and to help the Physician
prescribe evidence based standardized medical care
that will result in achieving adequate blood pressure
control among hypertensive patients. DSS is a soft-
ware that helps the Physician to (1) undertake a thor-
ough evaluation of risk factors (2) to classify the risk
level (3) to follow a software prompted algorithmic
guideline based drug management (which has been
developed based on Indian Hypertension guidelines II
[11] (2007) and (4) to give alerts on the counseling
on lifestyle changes and adherence to medication.
Mixed results have been shown for DSS in the man-
agement of hypertension in the developed world for
patient outcomes, but have shown that they improve
the Physician performance [12-15]. An improvement
in the quality of antihypertensive treatment, concur-
rently leading to a considerable reduction in drug
costs have been shown for DSS [16].
Very few studies having Decision support systems
(DSS) as an intervention report on patient outcomes
for cardiovascular disease in the Western world. Thepotential role of DSS for the management of blood
pressure among Indian hypertensives remains unclear.
We propose a cluster randomised trial that aims to
test the effectiveness and cost effectiveness of DSS
among Indian hypertensive patients.
Research question(s)
Are Decision Support Systems effective in lowering the
blood pressure (therefore the risk for CVD) and improving
the Quality of Life among hypertensive subjects in a Low
and Middle Income setting? Are Decision Support Systems




The objective of the study is to test the effectiveness
and compare the cost effectiveness and cost utility
among hypertensive subjects randomized to receive
DSS or a chart based algorithmic support system in
urban and rural areas of a district in the state of
Andhra Pradesh, India (baseline versus 12 months fol-
low up).
Aim
To develop, pilot test and implement a decision support
system for hypertensive subjects
1. To recruit and follow up hypertensive subjects for
12 months
2. To evaluate the effectiveness of DSS on CV risk
reduction and quality of life scores
3. To compare the CEA and CUA among hypertensive
subjects
Primary end point
 To compare the SBP (Systolic Blood Pressure) at 0
and 12 months among hypertensive patients
randomized to receive the DSS or the chart based
algorithmic support system
Secondary end point
 To compare the Quality of Life (QoL) scores at 0
and 12 months among hypertensive patients
randomized to receive the DSS or the chart based
algorithmic support system
 To compare the Cost effectiveness of the DSS versus
the chart based algorithmic support system at the
end of 12 months among hypertensive patients.
 To compare the Cost utility of the DSS versus the
chart based algorithmic support system at the end of
12 months among hypertensive patients.
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1. Adult male and female Indians in the age group of
35 – 64 years
2. Systolic blood pressure (SBP) of 140 mm Hg or
greater and/or diastolic blood pressure (DBP) of
90 mm Hg or greater (irrespective of
antihypertensive medications)
3. Informed written Consent formExclusion criterion
Hypertensive subjects who have been hospitalized within
the last 12 months and subjects with a history of cancer
(physician certified).
Randomly chosen Primary Health Care centers
(PHCs), matched on population size and literacy rate,
from a district in the state of Andhra Pradesh, India have
been cluster randomized to receive a DSS or a chart
based algorithmic support system (Figure 1). The study
site, Mahabubnagar district (AP) has four revenue divi-
sions (Wanaparthy, Nagarkurnool, Gadwal and
Narayanpet). Demographic details of all the PHCs, strati-
fied by the revenue divisions in Mahabubnagar district,
were line listed. The male to female ratio, age group dis-
tribution in the PHCs (based on census 2001 data) will
be collected from the Andhra Pradesh State Health and
Revenue departments. The PHCs will be stratified based
on similarity in the study age group demography details
(35-64 years of age) and gender distribution. Two PHCs,DSS– Decision support  system;CBS – Chart Based Su
PHC– Primary Health Care centre;
< 20 km – distance from PHC to secondary health care
> 20 km distance from PHC to secondary health care 
<20 km
PHC 1 PHC 2
DSS CBS
n = 125 n = 125
PHC 1 PHC 2
n = 125 n = 125
Physician DSS Chart based
support system
PHC 3 PHC 4 PHC 3 PHC 4
n = 125 n = 125 n = 125 n = 125
Figure 1 Plan for Randomisation.per intervention arm, will be randomly chosen from each
of the four divisions.
Physicians from the PHCs, who have been randomised
to receive the DSS arm would necessarily be trained and
instructed to follow the algorithms and prompts which
would arise out of the computer based software, for
management of BP. DSS is a software that helps the
Physician to (1) undertake a thorough evaluation of risk
factors that hypertensive patients may have for develop-
ing a cardiovascular disease, (2) to classify the risk level,
(3) to follow a software prompted algorithmic guideline
based drug management (which would be developed
based on Indian Hypertension guidelines II – 2007) and
(4) to give alerts on the counselling on lifestyle changes
and adherence to medication.
The chart based algorithmic support system will have
the guidelines and lifestyle advices printed as a poster
format which would then be pasted on the wall of the
PHC clinics. The Physicians from the PHCs, who have
been randomised to receive the chart based support arm,
would be instructed to follow the poster based guidelines
for management of BP. The risk factors that need to be
specifically elicited, classification of risk among hyperten-
sive subjects, flow chart for drug management and advice
for lifestyle interventions would be included as a simple
flow chart.
The DSS will be developed, pilot tested in 10% of sample
size and then implemented. Physician advice on lifestyle
interventions, which would include counselling on reduc-
tion of daily salt intake (reduction in papad and picklepport System;
 system is less than 20km;
system is more than 20km.
>20 km
PHC 1 PHC 2
DSS CBS
n = 125 n = 125
PHC 1 PHC 2
n = 125 n = 125
Physician DSS
PHC 3 PHC 4 PHC 3 PHC 4
n = 125 n = 125 n = 125 n = 125
Chart based
support system
Figure 2 Follow up of patients.
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and dalda), advice on benefits of brisk walking for 30 min
daily (5-7 days in a week), advice on benefits of smoking
cessation and adherence to treatment would be available
for patients randomized to DSS intervention arm at 0, 6
and 12 months and at 0 month for patients randomized to
receive chart based algorithmic support system. Physical
measurements such as height, weight, waist circumference,
pulse and Blood Pressure (BP) would be measured by a
digital BP monitor at 0, 6 and 12 months after study entry
(Figure 2).Blood pressure and pulse measurement
All Blood Pressure (BP) measurements taken by the
Physician will be performed in a standardised way
using digital blood pressure equipments (Model M5,
Omron) supplied and validated for the study. BP will
be measured on the right upper arm in the sitting
position, after a rest of 5 minutes. Using an appropri-
ate sized cuff (which will be recorded) connected to a
digital device, and the same arm (which will be
recorded), at a similar time of day (which will be
recorded), two measurements will be taken at a mi-
nute interval. Instructions will be given to the
Physicians to ensure that the lower edge of the blad-
der be placed 2-3 cm above the position of maximal
pulsation of the brachial artery in the arm, just above
the antecubital fossa. Care would be taken to ensure
that the cuff fits firmly, comfortably and is well
secured. The mean of the two readings will be used
for analysis.
Pulse measurements will be recorded by the digital
blood pressure equipment (Model M5, Omron), after a
rest of 5 minutes. The digital BP equipment records the
systolic, diastolic BP and the pulse in the same sitting,which would be recorded. The average of the two read-
ings will be used for the analysis.Height, weight and waist circumference measurements
The participants would be weighed in light indoor cloth-
ing with a digital weighing machine (Tanita weighing
Scale) with 100 g accuracy, which would be standardized
across all the centers. Height would be measured in bare
feet with Seca 213 Portable Freestanding stadiometer, ac-
curate to 1 mm. Care would be taken to ensure that all
the PHCs have the same equipment make, type and val-
idation procedures.
Data collection
Data on known cardiovascular risk factors (age, sex,
tobacco usage, history of diabetes mellitus, family his-
tory of premature coronary artery disease); any asso-
ciated clinical conditions (physician certified cerebro
vascular disease, cardiovascular disease, renal, vascular
diseases); target organ damage (physician certified left
ventricular hypertrophy, hypertensive retinopathy and
microalbuminuria); and quality of life scores (based
on WHO BREF questionnaire will be collected at 0, 6
and 12 months after randomization.
Quality of life questionnaire
World Health Organization (WHO) QoL BREF question-
naires, which have been validated in Indian settings for
chronic diseases, would be utilised in this study.
WHOQOL was designed as an international cross-cultur-
ally comparable quality of life assessment instrument [17].
This 26-item questionnaire has been tested and validated
in Hindi language [17], and tested in Indian patients suf-
fering from chronic diseases [18-20]. The questionnaire
would be translated into the local language (Telugu) and
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viewer would compare the translated and back translated
versions. The finalised questionnaire will be field tested in
10% of the proposed sample size for cultural appropriate-
ness. Questions which are deemed to hurt the cultural sen-
sitivity would be modified based on pilot test results. This
modified questionnaire will then be applied to the study.
Patients would be asked to read and answer the questions
on their own. In case of linguistic or other difficulties, the
questionnaire would be administered by interview.
Cost effectiveness analysis
A comparison of costs in monetary units with outcomes
in quantitative non-monetary units would done in the
Cost Effectiveness Analysis (CEA) [21]. Resources
required for intervention and values attached to those
resources and effects of treatment (either benefit or
harm) and values attached to those effects for the both
the groups will be compared to determine the cost ef-
fectiveness ratios. Cost effectiveness ratios, that is the
cost/outcome of different interventions, enable oppor-
tunity costs of each intervention to be compared.
Perspective
A third party payer perspective will be employed in this
project, as this would enable the tangible costs to be dir-
ectly compared between both the intervention arms.
Costs
The value of all goods, services, and other resources con-
sumed in providing health care or dealing with side
effects or other current and future consequences of
health care comprise the direct costs. Direct health care
and direct non health costs will be measured in this
study. The physician services, hospital services, drugs,
costs of the DSS software development, costs for charts
(posters) etc. involved in delivery of health care would
comprise the direct health care costs. Transportation to
and from the site of care would comprise the indirect
costs. Marginal costs analysis would be done in which





























4 mm of Hg 374 1115 1160 24
5 mm of Hg 239 713 741 16
6 mm of Hg 166 495 515 12
ICC= Intra Cluster correlation; DE=design effect; CV= coefficient of variation.to a comparator), would be analysed. The time horizon
for the costs involved would be for a duration of a year.
Outcomes
A reduction or worsening of systolic BP would be com-
pared (in non monetary terms). The time horizon would
be for a duration of one year.
Discounting
Thus, costs and outcomes will be discounted relative to
their present value (e.g., at a rate of three - five percent
per year) so as to account for the effect of time on the
value of the outcomes and costs, as they may have less
value in the future. Opportunity costs, which would be
reflected by discounting, would also be calculated.
Sensitivity analysis
Since any estimation of costs and outcomes has an un-
certainty element attached to it, a sensitivity analysis,
which would include a change in discount rates, would
be done to account for the changes in the cost-effective-
ness planes of one intervention compared to another.
Cost Effectiveness Ratio (CER)
The costs and outcomes for both the outcomes will be
calculated to yield a CER.
CER ¼ f Cost of DSS Cost of chart basedð Þ=
ðPrimary outcome of DSS primary outcome of
chart based interventionÞg
Cost utility analysis (CUA)
Measures costs in monetary units with outcomes in
terms of their utility attribute [Quality Adjusted Life
Years (QALYs)], i.e. cost per QALY. Cost utility would
be measured by Incremental Cost Effectiveness Ratios
(ICERs) between both the groups. ICER is a ratio be-
tween the differences in the cost involved between the
intervention proposed (in Indian National Rupees) and




























500 1490 1550 32
320 954 992 20
222 622 689 14
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sured on a Visual Analogue Scale (VAS) preference scale
with a maximum score of 100 (perfect or best imaginable
health) and minimum score of 0 (a quality of life which
equals worst health imagined) to measure the value of
the health state. The weights for the quality will be based
on the (1) preferences of the participants, (2) measured
on an interval scale and (3) anchored on perfect health
and death. The value of a health state would then be
combined with the time spent to calculate the total
QALYs. Usefulness, interpretability, and responsiveness
were the determining factors to choose VAS as the pre-
ferred way to measure the utility of the present health
state.
Sample size, sampling and recruitment
Table 1 gives the details of the sample size calculations.
To detect a difference of 4 mm Hg Systolic Blood
Pressure (SBP), the individual randomization sample size
has been calculated at 239 subjects per intervention arm
(SD of 19.5 mm for SBP [22]), with a 80% power and an
alpha of 0.05. Since, cluster randomization is being
attempted in this study, the individual randomization
sample size has to be adjusted by a design effect of 2.98
[design effect = 1+ (size of cluster -1) * Intra cluster
Correlation (ICC)]. The ICC for the clusters among the
Mahabubnagar district, AP, India (study site) has been
calculated to be 0.02 (based on the Indian sentinel sur-
veillance study done on a representative sample from 10
sites in India). Hence, the cluster adjusted sample size is
713 hypertensive patients (8 clusters with 125 subjects in
each cluster to allow for a 20% loss to follow up) per
intervention arm to detect a 4 mm Hg difference in
Systolic Blood Pressure (SBP) with a power of 80% and
an alpha of 0.05. After adjusting for the coefficient of
variation among the various clusters (CV= 0.25), the
sample size per intervention arm is 741, i.e. a total of 8
clusters (with equal cluster size of 100 each) would be
required per intervention arm.
Randomly chosen 8 PHCs – 4 urban and 4 rural
(homogenous in age and gender distribution) for each
intervention arm from a district in the State of AP, India
would form the study centers. Each PHC has an out
patient load of 50-100 patients/day. 2- 4 hypertensive
patients are being envisaged to be recruited per day by the
Physician per PHC from the patients attending the out pa-
tient clinic in the PHC. 10- 20 patients per week per PHC,
20- 40 per month per PHC and 125 patients in 4-6 months.
Study recruitment will last from June 2011 to Dec 2011.
Ethical principles
The participants would be given sufficient time to under-
stand the contents of the PIS (containing the study purpose,
duration, study procedures, right to withdrawal from thestudy, details of patient confidentiality, ethical committee
clearances, the study team details), and encouraged to ask
questions regarding any aspects of the study procedures
that they have not understood. The written informed con-
sent form will be read out aloud in the native language to
the study participants. They will be given an opportunity to
seek clarifications on any issues that have not been under-
stood. The signatures would be obtained by the Physician
who would be recruiting the hypertensive patients for the
study. The Physician would also sign and date the informed
consent form. One copy would be given to the patients and
one copy would be retained at the study site.
Discussion
Hypertension exerts a substantial burden on cardiovascular
health status and health care systems in India. Treatment
however can be costly and health care providers are inter-
ested in both whether treatments can offer improvements
in disease burden and whether they represent value for
money. Economic evaluations seek to resolve this issue by
producing results that can be used to inform and assist the
decision maker in allocating scarce health care resources.
DSS have been in place in the developed world to achieve a
balance between quality and cost of chronic disease health
care. To the best of the author’s knowledge, there have been
no randomized studies on DSS to enable policy makers to
find out the effectiveness, cost effectiveness and cost utility
analysis (CUA) of DSS for hypertensive patients in India.
The cluster randomised community trial aims to test a deci-
sion support system among Indian hypertensive patients.
Most of the previous studies on decision support system
have focused on physician performance, adherence and on
preventive care reminders. The uniqueness of the proposed
study lies in finding out the effectiveness of a decision
support system on patient related outcomes.
There are no known risks attributable to DSS per se. If
the participant is receiving DSS, the software assisting the
Physician prompts him or her to prescribe a particular class
of drug to manage and control blood pressure. If the partici-
pant is receiving the chart based algorithmic support sys-
tem, the decision to start or continue a drug is entirely up
to the Physician’s judgement. The software will be devel-
oped and pilot tested and will be based on standard Indian
Hypertension society guidelines (2007), which have been
endorsed by the Association of Physicians of India and the
Indian Cardiological Society. Adverse events that may
arise due to the drugs will be monitored and any serious
adverse events will be notified to the ethical committee
within 24 hours. Should any serious adverse events arise
the participants would be given the necessary care in the
primary health care centre and if necessary will be trans-
ferred to the Rural Hospital. Substitution of the drugs
causing adverse events is left to the decision of the
Physician. Blood will be drawn by a qualified and an
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quality of life questionnaire would be adapted from WHO
BREF questionnaire which has been validated in India. Pa-
tient confidentiality will be maintained at data entry and
data analysis stage.
Conclusion
This cluster randomised community trial aims to test
effectiveness, cost effectiveness and cost utility analysis of
a decision support system among Indian hypertensive
patients in comparison to a chart based algorithmic sup-
port system (that will have the guidelines and lifestyle
advices printed as a poster format). The utility of DSS in
management of hypertension will be tested in this pilot
study. Subsequent scale up of DSS and future studies of
DSS in management of different domains of cardiovascular
diseases are envisaged based on the results of this pilot
study.
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